CrystalGenomics bolsters commercial capabilities through BexPharm merger
This article was originally published in Scrip
Executive Summary
The South Korean drug discovery company CrystalGenomics is expecting to complete a merger with a local firm by the end of August, in a transaction designed to strengthen its independent sales capability in the domestic market.